Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infants and children according to the following age groups:~   * Healthy infants 2½ months of age (71 -79 days, inclusive), (only applicable to group I)~  * Healthy infants 3½ months of age (101 -109 days, inclusive), (only applicable to group II)~  * Healthy infants 6 months of age (only applicable to group III) (The age window is defined as the first day the subject turns 6 months of age up to the day before the subject turns 7 months of age).~  * Healthy children 2 to 5 years of age (only applicable to group IVa) (The age window is defined as the first day the subject turns 2 years of age up to the day before the subject turns 6 years of age).~  * Healthy children 6 to 10 years of age (only applicable to group IVb) (The age window is defined as the first day the subject turns 6 years of age up to the day before the subject turns 11 years of age).~  * Healthy infants 3 months of age (83-104 days, inclusive), (only applicable to Group V and VI).~2. For whom parent(s)/legal guardian(s) have given written informed consent according to local regulations after the nature of the study has been explained;~3. Available for all the visits scheduled in the study;~4. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.~Exclusion Criteria:~1. Individuals whose parent(s)/legal guardian(s) are unwilling or unable to give written informed consent to participate in the study;~2. Children's parents or legal guardian who are not able to comprehend and to follow all required study procedures for the whole period of the study.~3. History of any meningococcal B vaccine administration;~4. Previous ascertained or suspected disease caused by N. meningitidis;~5. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis;~6. History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component~7. Significant acute or chronic infection within the previous 7 days or temperature 38° C within the previous day of receiving the study vaccine;~8. Antibiotics treatment within 6 days prior to enrollment;~9. Individuals with history of allergy to vaccine components.~10. Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);~11. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, use of high dose systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within 14 days prior to enrollment (use of low or moderate doses of inhaled steroids is not an exclusion);~12. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days prior to enrollment.~13. Receipt of, or intent to immunize with, any other vaccine(s) within 7 days prior to enrollment.~14. Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.~15. Family members and household members of research staff~16. Individuals with history or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.~17. History of any meningococcal C vaccine administration (Only applicable to group V and VI).~18. History of any Pneumococcal vaccine administration (Only applicable to group V and VI).

- Gender: ALL
- Minimum Age: 71 Days
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- B_2h3h5_11 (Type: EXPERIMENTAL): Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
- B_3h5_11 (Type: EXPERIMENTAL): Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
- B_68_11 (Type: EXPERIMENTAL): Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
- B_02_2_5 (Type: EXPERIMENTAL): Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
- B_02_6_10 (Type: EXPERIMENTAL): Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
- BC_35_12 (Type: EXPERIMENTAL): Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
- C_35_12 (Type: EXPERIMENTAL): Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).